Kura Oncology announces positive phase II study for Tipifarnib in HRAS mutant disease

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Kura Oncology announced positive topline results from a phase II trial for tipifarnib in patients with HRAS mutant relapsed or refractory squamous cell carcinomas of the head and neck. The phase II trial achieved its primary endpoint prior to the completion of enrollment.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus-negative head-and-neck squamous cell carcinoma. More than half of study participants had 50% or more of their tumors shrink after receiving the immunotherapy drug nivolumab with chemotherapy, followed by response-adaptive chemo-radiation therapy. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login